Comment on Akbar et al., “Valbenazine-induced parkinsonism”

doi:10.1016/j.parkreldis.2020.01.011

Parkinsonism & Related Disorders

Volume 71, February 2020, Page 35

https://doi.org/10.1016/j.parkreldis.2020.01.011 Get rights and content

Abstract

This letter to the editor acknowledges the contribution of Akbar et al. to the field of tardive dyskinesia (TD) and provides important regulatory information about the potential for parkinson-like symptoms in patients with TD who are treated with valbenazine.

Section snippets

Funding sources

Not applicable.

Declaration of competing interest

Dr. Shah is a full-time employee of Neurocrine Biosciences, Inc., the manufacturer of INGREZZA® (valbenazine) capsules.

References (2)

U. Akbar et al.
Valbenazine-induced parkinsonism
Park. Relat. Disord.
(2020)
INGREZZA® (Valbenazine) Capsules. Prescribing Information
(2019)

Cited by (0)

View full text

CorrespondenceComment on Akbar et al., “Valbenazine-induced parkinsonism”

Abstract

Section snippets

Funding sources

Declaration of competing interest

Park. Relat. Disord.

INGREZZA® (Valbenazine) Capsules. Prescribing Information

Correspondence
Comment on Akbar et al., “Valbenazine-induced parkinsonism”